Trial Outcomes & Findings for PET-MRI in Diagnosing Patients With Cancer, Cardiac Diseases, or Neurologic Diseases (NCT NCT02084147)

NCT ID: NCT02084147

Last Updated: 2019-10-29

Results Overview

Overall image quality scores obtained from the two imaging modalities will be compared with the hypothesis that hybrid PET-MRI images is as good as PET-CT images or superior (not inferior) to the PET-CT images. Evaluation of overall image quality will be assessed using the following criteria: 1=excellent, 2=good, 3=acceptable, 4=poor, 5=not acceptable. A Wilcoxon (Mann-Whitney) rank-sum test with a 0.100 significance level will be used.

Recruitment status

COMPLETED

Study phase

NA

Target enrollment

72 participants

Primary outcome timeframe

Day 1

Results posted on

2019-10-29

Participant Flow

Participant milestones

Participant milestones
Measure
PET-CT and PET-MRI
Patients undergo PET-CT over approximately 30 minutes and PET-MRI over approximately 45-90 minutes. positron emission tomography: Undergo PET computed tomography: Undergo CT magnetic resonance imaging: Undergo MRI
Overall Study
STARTED
72
Overall Study
COMPLETED
72
Overall Study
NOT COMPLETED
0

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

PET-MRI in Diagnosing Patients With Cancer, Cardiac Diseases, or Neurologic Diseases

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
PET-CT and PET-MRI
n=72 Participants
Patients undergo PET-CT over approximately 30 minutes and PET-MRI over approximately 45-90 minutes. positron emission tomography: Undergo PET computed tomography: Undergo CT magnetic resonance imaging: Undergo MRI
Age, Customized
10-19 years
4 Participants
n=5 Participants
Age, Customized
20-29 years
1 Participants
n=5 Participants
Age, Customized
30-39 years
3 Participants
n=5 Participants
Age, Customized
40-49 years
4 Participants
n=5 Participants
Age, Customized
50-59 years
25 Participants
n=5 Participants
Age, Customized
60-69 years
17 Participants
n=5 Participants
Age, Customized
70-79 years
14 Participants
n=5 Participants
Age, Customized
80-89 years
4 Participants
n=5 Participants
Sex: Female, Male
Female
30 Participants
n=5 Participants
Sex: Female, Male
Male
42 Participants
n=5 Participants
Ethnicity (NIH/OMB)
Hispanic or Latino
0 Participants
n=5 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
31 Participants
n=5 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
41 Participants
n=5 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
n=5 Participants
Race (NIH/OMB)
Asian
0 Participants
n=5 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
n=5 Participants
Race (NIH/OMB)
Black or African American
6 Participants
n=5 Participants
Race (NIH/OMB)
White
50 Participants
n=5 Participants
Race (NIH/OMB)
More than one race
8 Participants
n=5 Participants
Race (NIH/OMB)
Unknown or Not Reported
8 Participants
n=5 Participants
Region of Enrollment
United States
72 participants
n=5 Participants

PRIMARY outcome

Timeframe: Day 1

Population: No data was obtained from this study group as the patient cohort was inconsistent

Overall image quality scores obtained from the two imaging modalities will be compared with the hypothesis that hybrid PET-MRI images is as good as PET-CT images or superior (not inferior) to the PET-CT images. Evaluation of overall image quality will be assessed using the following criteria: 1=excellent, 2=good, 3=acceptable, 4=poor, 5=not acceptable. A Wilcoxon (Mann-Whitney) rank-sum test with a 0.100 significance level will be used.

Outcome measures

Outcome data not reported

PRIMARY outcome

Timeframe: Day 1

Population: No data was obtained from this study group as the patient cohort was inconsistent

Lesion based SUV will be estimated and compared for PET-MR and PET-CT images in normal organs and compared. A two-sided two-sample t-test will be used to show significance of difference.

Outcome measures

Outcome data not reported

PRIMARY outcome

Timeframe: Day 1

Population: No data was obtained from this study group as the patient cohort was inconsistent

A two-sided z-test will be used to detect the difference in the area under the curve showing the sensitivity, specificity, positive and negative predictive values as well as accuracy of diagnostic information.

Outcome measures

Outcome data not reported

PRIMARY outcome

Timeframe: Day 1

Population: No data was obtained from this study group as the patient cohort was inconsistent

Statistical difference in time between PET-MRI versus sequential approach for PET-CT plus MRI. Workflow with shortest timely efforts and sufficient diagnostic information will be established as routine procedure.

Outcome measures

Outcome data not reported

PRIMARY outcome

Timeframe: Day 1

Population: No data was obtained from this study group as the patient cohort was inconsistent

Dose measurements will be used to calculate effective radiation dose in each patient. Dose calculations of effective dose will be used to estimate dose savings in omitting the CT component of PET-CT. Statistical tests will use a 0.10 significance level and will be 2-sided

Outcome measures

Outcome data not reported

Adverse Events

PET-CT and PET-MRI

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Philipp Frank Graner

Cleveland Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center

Phone: +1 216-844-8275

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place